



United States of America
FEDERAL TRADE COMMISSION
Southwest Region

1999 Bryan St., Ste. 2150
Dallas, Texas 75201

May 22, 2020

WARNING LETTER

VIA EMAIL TO lab@innovationcompounding.com

Innovation Compounding
6095 Pine Mountain Road NW, Suite 108
Kennesaw, Georgia 30152

Re: Unsubstantiated Claims for Coronavirus Prevention or Treatment

To Whom It May Concern,

This is to advise you that FTC staff has reviewed your website at <https://innovationcompounding.com/> on May 17, 2020. We have determined that you are unlawfully advertising that intravenous Vitamin C treats or prevents Coronavirus Disease 2019 (COVID-19).

Some examples of Coronavirus treatment or prevention claims on your website include:

- In marketing materials titled “Coronavirus: Is High-Dose Vitamin C the Answer?”, you claim that “A lack of vitamin C has been long known to increase susceptibility to viruses... Supporting various cellular functions of both the innate and adaptive immune system, vitamin C is well known for its contribution to the body’s immune defense. **So what might this mean for treatment?** China is conducting a clinical trial of 24,000 mg/day of intravenous vitamin C to treat patients with coronavirus and severe respiratory complications.... At Innovation Compounding, we provide high dose IV Vitamin C Cocktail Infusions in a variety of doses to help patients who need intense immune support.”

It is unlawful under the FTC Act, 15 U.S.C. § 41 *et seq.*, to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the product identified above. Thus, any Coronavirus-

related prevention or treatment claims regarding such product are not supported by competent and reliable scientific evidence. You must immediately cease making all such claims.

You are also advised to review all other claims for your products and immediately cease making claims that are not supported by competent and reliable scientific evidence.

Within 48 hours, please send a message to James E. Elliott via electronic mail at jelliott@ftc.gov describing the specific actions you have taken to address the FTC's concerns. If you have any questions regarding compliance with the FTC Act, please contact Zachary A. Keller at zkeller@ftc.gov.

Very truly yours,

Dama J. Brown
Regional Director
Southwest Region